The invention relates to a device and a method for UV antisepsis, in particular for intracorporeal in vivo UV antisepsis on the human and animal body in the event of colonization with multiresistant pathogens (MRPs) such as methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE). The device comprises a light emitting diode chip, LED chip, configured to emit radiation in the UVC spectral range, wherein the LED chip forms a light emitting diode, LED, with a package; a spectral filter element set up to limit the radiation emitted by the LED chip substantially to wavelengths below 235 nm; and an optical element for directional emission of the radiation emitted by the LED.

In some aspects, the techniques described herein relate to a wound care device, including: an ultraviolet (UV) light configured to emit UV light and an infrared (IR) light configured to emit IR light. A method is also disclosed.

Certain exemplary embodiments can provide an apparatus and method for generating at least one radiation. The exemplary apparatus and/or method can selectively kill and/or affect at least one bacteria. For example, a radiation source first arrangement can be provided which is configured to generate at least one radiation having one or more wavelengths provided in a range of about 190 nanometers (nm) to about 230 nm, and at least one second arrangement can be provided which is configured to prevent the at least one radiation from having any wavelength that is outside of the range.

A therapy system includes a therapy output device that includes light sources and a controller. The light sources are configured to output electromagnetic radiation at different peak wavelengths. The controller is configured to operate the light sources to output the electromagnetic radiation to differ between a first therapy program and second therapy program by at least one of peak wavelengths, irradiance of one or more of the peak wavelengths, or energy density of the one or more peak wavelengths.

In one aspect, embodiments relate to a system for preventative dental laser treatment that ensures even irradiation of a laser beam. The system includes, a laser arrangement configured to generate the laser beam. The laser beam has one or more of a super-Gaussian energy profile and a transverse ring mode. The system also includes a focus optic. The focus optic is configured to converge the laser beam with a numerical aperture of 0.1 or less to a focal region. The system also includes a hand piece configured to direct the laser beam at a surface of a dental hard tissue. The system additionally includes a controller. The controller is configured to control one or more parameters of the laser source, such that a portion of the surface of the dental hard tissue is heated to a temperature in a range between 400° Celsius and 1300° Celsius.

Disclosed are a sensitizing composition for thermal cancer therapy using electromagnetic waves and a method of treating cancer using the composition. The sensitizing composition includes a metal ion, a metal ion-bound material, metal ion-noncovalently bound apotransferrin (transferrin), or a metal ion-noncovalently bound apotransferrin derivative. The sensitizing composition enables selective delivery of the metal ion to tumorous tissue when administered in vivo, and thus the generation of heat in tumorous tissue in which the metal ion accumulates is increased upon thermal cancer therapy using electromagnetic waves, thereby maximizing efficacy of thermal cancer therapy using electromagnetic waves in treating cancer. Thermal therapy using the sensitizing composition effectively treats cancer without pain or side effects and is thus expected to be widely useful in anticancer treatment as monotherapy, and/or in combination with chemotherapy, radiation therapy, or a combination thereof, ultimately increases the potential to cure cancer.

The present invention involves a programmable or static multiwavelength LED lighting fixture that is capable of emitting wavelengths of light both for visual perception and other key physiological processes. The lighting fixture produces emitted spectra, wherein one portion of the emitted spectra serves visual perception and at least one portion of the emitted spectra is selected from the group consisting of 290-315 nm; 360-400 nm; 470-490 nm; and 600-1400 nm.

A software-implemented process for preventing reuse of a replaceable cleansing attachment includes detecting, via a chip in the replaceable cleansing attachment, that the replaceable cleansing attachment is attached to a base. The method also includes during a first use, receiving, at an acoustic transducer, high-frequency current from the base, wherein the acoustic transducer converts the high-frequency current into sound waves to assist in an abrasive removal of wound coatings. And the method includes recording, to the chip, an indication of the first use of the replaceable cleansing attachment, wherein the chip is configured to prevent a second use of the replaceable cleansing attachment when the chip has the indication of first use of the replaceable cleansing attachment stored thereon.

The present disclosure relates to systems, methods, and uses of systems for treating a skin condition with phototherapy. A system comprises (a) a phototherapy device comprising a phototherapy light source; (b) a patient computing device comprising a processor and a memory, the patient computing device configured to: transmit a first signal to the phototherapy device enabling operation of the phototherapy device according to one or more conditional prescription parameters, activate the phototherapy light source, and transmit a second signal reporting operation of the phototherapy device; and (c) a server configured to communicate with the patient computing device and receive the second signal.

A composite implant for sustained release of a therapeutic agent in an ocular area of a subject. The composite implant comprises a matrix of photopolymerized polymer formed from a photopolymerizable composition, a biodegradable polymer contained within the matrix, and a therapeutic agent dispersed or dissolved between the matrix and/or biodegradable polymer, wherein the implant is formed from an ocular composition comprising 99 to 60% (w/w) of the photopolymerizable composition. The composite implant can be used in methods of delivering a therapeutic agent to an ocular area in a subject in need thereof, particularly by injecting the implant into the ocular area. Methods of preparing the composite implant are also disclosed.